Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Lu, Yu; Zhu, Di; Le, Quynh Chi; Wang, Yuji; Wang, Wei

doi:10.1039/d2nr02994d

Cited by 27 publications

(13 citation statements)

References 312 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current developments in nano drug delivery systems have focused on ruthenium-nanomedicine in the form of liposome-Ru nanoformulation, Ru–Se nanoparticles, Ru–Au nanocomposites, Ru–Si nanomaterials to obtain the targeted delivery and enhanced therapeutic activity . Very recently, Wang et al summarized the development of carrier nanomedicine, and self-assembly of carrier-free nanomedicine to deliver ruthenium complexes . In our laboratory, we also have developed a Ru(arene)metallopolymer-gold nanoconjugate to enhance the in vitro anticancer activity of Ru-arene complex in colorectal cancer cells .…”

Section: Challenges and Chances In Clinical Translation Of Ruthenium ...mentioning

confidence: 96%

“…154 Very recently, Wang et al summarized the development of carrier nanomedicine, and self-assembly of carrier-free nanomedicine to deliver ruthenium complexes. 155 In our laboratory, we also have developed a Ru(arene)metallopolymer-gold nanoconjugate to enhance the in vitro anticancer activity of Ru-arene complex in colorectal cancer cells. 156 Also, we found that the cancer cell uptake of the liposome-encapsulated Ru(arene) complex is 20 times enhanced, and the total ROS formation in cancer cells is also significantly increased compared to the nonencapsulated complex.…”

Section: Challenges and Chances In Clinical Translation Of Ruthenium ...mentioning

confidence: 99%

See 1 more Smart Citation

Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal–Drug Synergism in Metallodrug Design

Sumithaa

Ganeshpandian

2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

A novel strategy in metallodrug discovery today is incorporating clinically approved drugs into metal complexes as coordinating ligands. Using this strategy, various drugs have been repurposed to prepare organometallic complexes to overcome the resistance of drugs and to design promising alternatives to currently available metal-based drugs. Notably, the combination of organoruthenium moiety and clinical drug in a single molecule has been shown, in some instances, to enhance pharmacological activity and reduce toxicity in comparison to the parent drug. Thus, for the past two decades, there has been increasing interest in exploiting metal–drug synergism to develop multifunctional organoruthenium drug candidates. Herein, we summarized the recent reports of rationally designed half-sandwich Ru(arene) complexes containing different FDA-approved drugs. This review also focuses on the mode of coordination of drugs, ligand-exchange kinetics, mechanism of action, and structure–activity relationship of organoruthenated complexes containing drugs. We hope this discussion may serve to shed light on future developments in ruthenium-based metallopharmaceuticals.

show abstract

Section: Challenges and Chances In Clinical Translation Of Ruthenium ...mentioning

confidence: 96%

Section: Challenges and Chances In Clinical Translation Of Ruthenium ...mentioning

confidence: 99%

Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal–Drug Synergism in Metallodrug Design

Sumithaa

Ganeshpandian

2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Recently, a lot of TMCs, such as Ru (II), Pt (IV), and Rh (III) PSs, as well as Ir (III) and Os (II) complexes, with attractive photobiological properties have been designed and developed for medical treatment drugs [91]. Excitingly, McFarland and coworkers reported the first Ru (II)‐based PS TLD1433 to enter clinical trials, which will enter into a multicenter phase II study for non‐muscle‐invasive bladder cancer [92]. Owing to large Stokes shifts, high ROS efficiency, and high photochemical properties, Ir‐complexes have the potential to be a promising PDT agent.…”

Section: The Acq‐to‐aie Transformation Of Transition Metal Complex‐pssmentioning

confidence: 99%

Reviewing the evolutive ACQ‐to‐AIE transformation of photosensitizers for phototheranostics

Zhu,

Huang,

et al. 2023

Luminescence

View full text Add to dashboard Cite

Photodynamic therapy (PDT) represents an emerging noninvasive treatment technique for cancers and various nonmalignant diseases, including infections. During the process of PDT, the physical and chemical properties of photosensitizers (PSs) critically determine the effectiveness of PDT. Traditional PSs have made great progress in clinical applications. One of the challenges is that traditional PSs suffer from aggregation‐caused quenching (ACQ) due to their discotic structures. Recently, aggregation‐induced emission PSs (AIE‐PSs) with a twisted propeller‐shaped conformation have been widely concerned because of high reactive oxygen species (ROS) generation efficiency, strong fluorescence efficiency, and resistance to photobleaching. However, AIE‐PSs also have some disadvantages, such as short absorption wavelengths and insufficient molar absorption coefficient. When the advantages and disadvantages of AIE‐PSs and ACQ‐PSs are complementary, combining ACQ‐PSs and AIE‐PSs is a “win‐to‐win” strategy. As far as we know, the conversion of traditional representative ACQ‐PSs to AIE‐PSs for phototheranostics has not been reviewed. In the review, we summarize the recent progress on the ACQ‐to‐AIE transformation of PSs and the strategies to achieve desirable theranostic applications. The review would be helpful to design more efficient ACQ‐AIE‐PSs in the future and to accelerate the development and clinical application of PDT.

show abstract

“…Indeed, in the last decades, a huge number of antiproliferative Ru-based complexes have been subjected to in-depth preclinical studies, and the literature reveals that progress in perspective Ru-based anticancer agents is outstanding (for recent reviews, see refs. [ 1 , 2 , 3 , 4 ]). Primarily, both organic and inorganic Ru(II) and Ru(III) complexes have been, so far, proposed, sharing special electronic and steric features within a wide repertoire of possible chemical ligands and decorations.…”

Section: Introductionmentioning

confidence: 99%

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Ferraro

Bocchetti

Riccardi

et al. 2023

IJMS

View full text Add to dashboard Cite

Based on compelling preclinical evidence concerning the progress of our novel ruthenium-based metallotherapeutics, we are focusing research efforts on challenging indications for the treatment of invasive neoplasms such as the triple-negative breast cancer (TNBC). This malignancy mainly afflicts younger women, who are black, or who have a BRCA1 mutation. Because of faster growing and spreading, TNBC differs from other invasive breast cancers having fewer treatment options and worse prognosis, where existing therapies are mostly ineffective, resulting in a large unmet biomedical need. In this context, we benefited from an experimental model of TNBC both in vitro and in vivo to explore the effects of a biocompatible cationic liposomal nanoformulation, named HoThyRu/DOTAP, able to effectively deliver the antiproliferative ruthenium(III) complex AziRu, thus resulting in a prospective candidate drug. As part of the multitargeting mechanisms featuring metal-based therapeutics other than platinum-containing agents, we herein validate the potential of HoThyRu/DOTAP liposomes to act as a multimodal anticancer agent through inhibition of TNBC cell growth and proliferation, as well as migration and invasion. The here-obtained preclinical findings suggest a potential targeting of the complex pathways network controlling invasive and migratory cancer phenotypes. Overall, in the field of alternative chemotherapy to platinum-based drugs, these outcomes suggest prospective brand-new settings for the nanostructured AziRu complex to get promising goals for the treatment of metastatic TNBC.

show abstract

Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy

Abstract: Ruthenium complex is an important compound group for antitumor drug research and development. NAMI-A, KP1019, TLD1433 and other ruthenium complexes have entered clinical research. In recent years, the research on...

Cited by 27 publications

References 312 publications

Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal–Drug Synergism in Metallodrug Design

Half-Sandwich Ruthenium Arene Complexes Bearing Clinically Approved Drugs as Ligands: The Importance of Metal–Drug Synergism in Metallodrug Design

Reviewing the evolutive ACQ‐to‐AIE transformation of photosensitizers for phototheranostics

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Contact Info

Product

Resources

About